Robert J. Fox

Mellen Center for Treatment and Research in Multiple Sclerosis, Cleveland Clinic

Research Area

Biography

Robert J. Fox has not added Biography.
If you are Robert J. Fox and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 22	2019

Other Publications

Article	Year
Multiple sclerosis: disease markers accelerate progress. Lancet neurology\| PubMed ID: 14693099	2004
New directions in MS therapeutics: vehicles of hope. Trends in immunology\| PubMed ID: 15530830	2004
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 15794385	2005
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain : a journal of neurology\| PubMed ID: 16230319	2006
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Annals of neurology\| PubMed ID: 16392116	2006
Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleveland Clinic journal of medicine\| PubMed ID: 16444920	2006
Multiple sclerosis: treating symptoms, and other general medical issues. Cleveland Clinic journal of medicine\| PubMed ID: 16478042	2006
Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a? Nature clinical practice. Neurology\| PubMed ID: 16932486	2005
Treatment of Susac syndrome with gamma globulin and corticosteroids. Journal of the neurological sciences\| PubMed ID: 17052732	2006
Optimal reference population for the multiple sclerosis functional composite. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 17468446	2007
Neurogenesis in the chronic lesions of multiple sclerosis. Brain : a journal of neurology\| PubMed ID: 18669500	2008
Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 18701575	2008
A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury. Archives of neurology\| PubMed ID: 18779420	2008
Picturing multiple sclerosis: conventional and diffusion tensor imaging. Seminars in neurology\| PubMed ID: 18843574	2008
Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Archives of neurology\| PubMed ID: 19139298	2009
Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 20670982	2010
Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR. American journal of neuroradiology\| PubMed ID: 20947644	2011
Web-based self-management for patients with multiple sclerosis: a practical, randomized trial. Telemedicine journal and e-health : the official journal of the American Telemedicine Association\| PubMed ID: 21214498	2011
Advanced MRI in multiple sclerosis: current status and future challenges. Neurologic clinics\| PubMed ID: 21439446	2011
Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Annals of neurology\| PubMed ID: 21446020	2011
Chronic cerebrospinal venous insufficiency: a Kuhnian paradigm shift or another fad? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne\| PubMed ID: 21969409	2011
Advances in the management of PML: focus on natalizumab. Cleveland Clinic journal of medicine\| PubMed ID: 22123933	2011
A validation study of multicenter diffusion tensor imaging: reliability of fractional anisotropy and diffusivity values. AJNR. American journal of neuroradiology\| PubMed ID: 22173748	2012
Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology\| PubMed ID: 22282644	2012
Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and reality. Current treatment options in cardiovascular medicine\| PubMed ID: 22311713	2012
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 22917690	2012
A technical approach to dissecting and assessing cadaveric veins pertinent to chronic cerebrospinal venous insufficiency in multiple sclerosis. Neurological research\| PubMed ID: 22971470	2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. The New England journal of medicine\| PubMed ID: 22992072	2012
Cortical remyelination: a new target for repair therapies in multiple sclerosis. Annals of neurology\| PubMed ID: 23076662	2012
Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology\| PubMed ID: 23269598	2013
High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology\| PubMed ID: 28298551	2017
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 23303880	2013
Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Annals of neurology\| PubMed ID: 23595422	2013
Multiple sclerosis treatment: risk mitigation. Continuum (Minneapolis, Minn.)\| PubMed ID: 23917104	2013
Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder? The International journal of neuroscience\| PubMed ID: 24111490	2014
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Current medical research and opinion\| PubMed ID: 24131282	2014
Hydration status substantially affects chronic cerebrospinal venous insufficiency assessments. Neurology. Clinical practice\| PubMed ID: 24175155	2013
Injury to a specific neural pathway detected by ultra-high-field MRI. Neurology\| PubMed ID: 24285615	2014
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database. International journal of MS care\| PubMed ID: 24453783	2013
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology\| PubMed ID: 24682966	2014
Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology\| PubMed ID: 24871874	2014
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 24990854	2015
Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical database. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 25112816	2015
Risk stratification and mitigation multiple sclerosis. Multiple sclerosis and related disorders\| PubMed ID: 25221744	2014
Biomarkers for MS: unpuzzling the progressive multiple sclerosis puzzle. Neurology\| PubMed ID: 25253742	2014
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and... Clinical therapeutics\| PubMed ID: 25315404	2014
Identifying the start of multiple sclerosis injury: a serial DTI study. Journal of neuroimaging : official journal of the American Society of Neuroimaging\| PubMed ID: 25370339	2014
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology\| PubMed ID: 25681448	2015
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of clinical and translational neurology\| PubMed ID: 25750916	2015
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. The Lancet. Neurology\| PubMed ID: 25772899	2015
Observations on the brain vasculature in multiple sclerosis: A historical perspective. Multiple sclerosis and related disorders\| PubMed ID: 25878003	2014
Comment: A better measuring stick for walking in multiple sclerosis. Neurology\| PubMed ID: 25878181	2015
Progressive multiple sclerosis. Current opinion in neurology\| PubMed ID: 25887766	2015
Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 25948627	2015
Risk tolerance to MS therapies: Survey results from the NARCOMS registry. Multiple sclerosis and related disorders\| PubMed ID: 26008941	2015
Chronic cerebrospinal venous insufficiency: pitfalls and perils of sonographic assessment. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine\| PubMed ID: 26014330	2015
The Future of Research in Multiple Sclerosis. JAMA neurology\| PubMed ID: 26053218	2015
No Association of Chronic Cerebrospinal Venous Insufficiency with Multiple Sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques\| PubMed ID: 26194114	2016
Progressive MS: from pathophysiology to drug discovery. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 26362902	2015
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International journal of MS care\| PubMed ID: 26472945	2015
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study. Neurology and therapy\| PubMed ID: 26525536	2015
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical therapeutics\| PubMed ID: 26526385	2015
Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry. Neurodegenerative disease management\| PubMed ID: 26611264	2015
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and therapy\| PubMed ID: 26662361	2015
Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus. PloS one\| PubMed ID: 26800522	2016
Refining diagnosis of multiple sclerosis with revised MRI criteria. The Lancet. Neurology\| PubMed ID: 26822747	2016
Reassessing the risk of natalizumab-associated PML. Journal of neurovirology\| PubMed ID: 26843383	2016
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONF... Neurology and therapy\| PubMed ID: 26932146	2016
Relationship between symptom change, relapse activity and disability progression in multiple sclerosis. Journal of the neurological sciences\| PubMed ID: 26944131	2016
Erratum to: Reassessing the risk of natalizumab-associated PML. Journal of neurovirology\| PubMed ID: 27026534	2016
Relapses in multiple sclerosis: Relationship to disability. Multiple sclerosis and related disorders\| PubMed ID: 27063617	2016
JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection. PloS one\| PubMed ID: 27191595	2016
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 27207449	2017
Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. International journal of MS care\| PubMed ID: 27252601	2016
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. Neurology. Clinical practice\| PubMed ID: 27347439	2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary clinical trials\| PubMed ID: 27521810	2016
Quantitative quality assurance in a multicenter HARDI clinical trial at 3T. Magnetic resonance imaging\| PubMed ID: 27587227	2017
Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging. AJNR. American journal of neuroradiology\| PubMed ID: 27659189	2017
Imaging as an Outcome Measure in Multiple Sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics\| PubMed ID: 27699722	2017
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 27729555	2017
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Current medical research and opinion\| PubMed ID: 27733070	2017
Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. Neurology. Clinical practice\| PubMed ID: 27847682	2016
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet (London, England)\| PubMed ID: 27889191	2017
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple sclerosis and related disorders\| PubMed ID: 27919497	2016
Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 28156185	2017
Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 28279128	2018
Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of comparative effectiveness research\| PubMed ID: 28350241	2017
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 28381130	2018
Autologous hematopoietic stem cell transplantation for MS: Safer than previously thought. Neurology\| PubMed ID: 28455384	2017
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clinical therapeutics\| PubMed ID: 28751099	2017
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and ... Neurology and therapy\| PubMed ID: 28770420	2017
DNA methylation in demyelinated multiple sclerosis hippocampus. Scientific reports\| PubMed ID: 28821749	2017
T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis. Annals of neurology\| PubMed ID: 28833377	2017
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Multiple sclerosis journal - experimental, translational and clinical\| PubMed ID: 28890796	2017
Advancing trial design in progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 29041871	2017
Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants. Neurology. Clinical practice\| PubMed ID: 29185555	2017
Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. Multiple sclerosis and related disorders\| PubMed ID: 29275057	2018
Long-term registries: Answering tough questions with big data? Neurology. Clinical practice\| PubMed ID: 29377024	2016
Tissue Markers for Acute Multiple Sclerosis Treatment Response-A Step Toward Personalized Medicine. JAMA neurology\| PubMed ID: 29404560	2018
Dimethyl fumarate for relapsing MS. Neurology. Clinical practice\| PubMed ID: 29473631	2013
A survey of dietary characteristics in a large population of people with multiple sclerosis. Multiple sclerosis and related disorders\| PubMed ID: 29510324	2018
Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Ph... Clinical therapeutics\| PubMed ID: 29523369	2018
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet (London, England)\| PubMed ID: 29576505	2018
Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology\| PubMed ID: 29602911	2018
Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric? Multiple sclerosis journal - experimental, translational and clinical\| PubMed ID: 29854415	2018
Technical Note: Retrospective reduction in systematic differences across scanner changes by accounting for noise floor effects in diffusion tensor imaging. Medical physics\| PubMed ID: 29998491	2018
Prospects of siponimod in secondary progressive multiple sclerosis. Therapeutic advances in neurological disorders\| PubMed ID: 30038666	2018
Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial. Magnetic resonance imaging\| PubMed ID: 30048675	2018
Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurology. Clinical practice\| PubMed ID: 30105172	2018
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurology. Clinical practice\| PubMed ID: 30140580	2018
Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. The Lancet. Neurology\| PubMed ID: 30143361	2018
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. The New England journal of medicine\| PubMed ID: 30157388	2018
Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs\| PubMed ID: 30255442	2018
Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis. Neurology. Clinical practice\| PubMed ID: 30588376	2018
Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Multiple sclerosis and related disorders\| PubMed ID: 30690340	2019
A survey of risk tolerance to multiple sclerosis therapies. Neurology\| PubMed ID: 30867272	2019
Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology\| PubMed ID: 30918100	2019
The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. Multiple sclerosis and related disorders\| PubMed ID: 31063935	2019
Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 31079537	2019
Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 31161917	2019
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC neurology\| PubMed ID: 31176355	2019
The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 31218918	2019
Demyelinating lesions and progressive MS: Location, location, location. Neurology\| PubMed ID: 31289147	2019